Wrap Text
Tax treatment of ordinary share dividend for shareholders on the South African register
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
(‘Mediclinic’, the ‘Company’, or the ‘Group’)
10 August 2022
TAX TREATMENT OF ORDINARY SHARE DIVIDEND FOR SHAREHOLDERS ON THE SOUTH AFRICAN REGISTER
Background
Shareholders on the South African register of the Company are referred to Mediclinic’s
announcement of the results for the year ended 31 March 2022 and proposed dividend
announcement released on the Stock Exchange News Service and on the Regulatory News
Service on 25 May 2022, confirming that the Board of Directors of Mediclinic proposed a final
dividend from retained earnings of 3.00 pence per ordinary share for the year ended 31 March
2022 for approval by the Company’s shareholders at the annual general meeting on Thursday,
28 July 2022.
The final dividend will be paid on Friday, 26 August 2022 to all ordinary shareholders who are
on the register of members at the close of business on the record date of Friday, 5 August 2022.
Shareholders on the South African register will be paid the ZAR cash equivalent of 59.53230
cents (47.62584 cents net of dividend withholding tax) per share. A dividend withholding tax of
20% will be applicable to all shareholders on the South African register who are not exempt
therefrom. The ZAR cash equivalent has been calculated using the following exchange rate:
£1: ZAR19.8441, being the 5-day average ZAR/GBP exchange rate (Bloomberg) on Friday, 20
May 2022 at 3:00pm GMT.
Tax treatment for shareholders on the South African register
South African tax resident shareholders on the South African register:
In terms of the Company’s Dividend Access Trust structure, eligible South African tax resident
shareholders on the South African register set out below will receive the full dividend, namely
59.53230 cents per share, from the Dividend Access Trust and therefore regarded as a local
South African dividend. For purposes of South African dividend withholding tax, the entire
dividend of 59.53230 cents per share is taxable at a rate of 20%, unless an applicable
exemption applies:
1. in the case of shares held in certificated form, eligible shareholders who are registered
on the South African register with an address in South Africa (other than PLC Nominees
Proprietary Limited (or any successor entity through which shares held in dematerialised
form are held)); and
2. in the case of shares held in dematerialised form, in respect of whom the South African
transfer secretaries of the Company have determined, in good faith and by reference to
the information provided to them by the eligible shareholders and/or their brokers and/or
central securities depository participants, that such eligible shareholders are either (i) tax
resident in South Africa or (ii) have an address in South Africa and have not expressly
indicated that they are not tax resident in South Africa as at the dividend record date.
Non-South African tax resident shareholders on the South African register:
Non-South African tax resident shareholders on the South African register will be paid the
dividend by the Company in the usual way and not through the Dividend Access Trust. The
entire dividend of 59.53230 cents per share payable to such shareholders will therefore be
regarded as a foreign dividend and exempt from South African dividend withholding tax,
provided that the relevant exemption forms have been completed and submitted as prescribed.
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South
Africa in 1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and
the Middle East.
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the
continuum of care in such a way that the Group will be regarded as the most respected and
trusted provider of healthcare services by patients, medical practitioners, funders and
regulators of healthcare in each of its markets.
At 30 June 2022, Mediclinic comprised 74 hospitals, five subacute hospitals, two mental health
facilities, 20 day case clinics and 23 outpatient clinics. The Swiss operations included 17
hospitals and four day case clinics with around 1 900 inpatient beds; Southern Africa operations
included 50 hospitals (three of which in Namibia), five subacute hospitals, two mental health
facilities and 14 day case clinics (four of which operated by Intercare) across South Africa, and
around 8 650 inpatient beds; and the Middle East operated seven hospitals, two day case clinics
and 23 outpatient clinics with around 1 000 inpatient beds in the UAE. In addition, under
management contract the Middle East will open a 200-bed hospital in the Kingdom of Saudi
Arabia in 2023.
The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom,
with secondary listings on the JSE in South Africa and the Namibian Stock Exchange in
Namibia.
Mediclinic also holds a 29.7% interest in Spire Healthcare Group plc, a leading private
healthcare group based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Caroline Emmet
+44 (0)333 300 1930
Investor Relations
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – United Kingdom
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS
Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 10-08-2022 01:00:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
